Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT07294170
Recruiting Observational

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170 · tracked via the Priya Life Science Belgium tracker
Sponsor
argenx
Phase
Observational
Started
2025-12-19
Last updated
2026-09-24

Condition(s) studied

Myasthenia GravisMGgMGGeneralized Myasthenia GravisGeneralized Myasthenia Gravis (gMG)AChR-Ab Seropositive Generalized Myasthenia Gravis

Investigational drug(s) / intervention(s)

Efgartigimod IV →Empasiprubart IV →Placebo IVEfgartigimod PH20 SC PFS

Efgartigimod IV: Intravenous infusion of efgartigimod

Empasiprubart IV: Intravenous infusion of empasiprubart

Placebo IV: Intravenous infusion of placebo

Efgartigimod PH20 SC PFS: Subcutaneous administration of Efgartigimod PH20 via pre-filled syringe (PFS)

Study summary

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies * Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment * If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening Exclusion Criteria: * Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk * Is MGFA (Myasthenia Gravis Foundation of America) Class V

Primary outcome measure(s)

Trial sites (36)

FacilityCityRegionStatus
Profound Research LLC - Carlsbad Carlsbad California Recruiting
Visionary Investigators Network Miami Florida Recruiting
Visionary Investigators Network Miami Florida Recruiting
University of South Florida Tampa Florida Recruiting
Massachusetts General Hospital Boston Massachusetts Recruiting
Henry Ford Health System Detroit Michigan Recruiting
Profound Research LLC at Las Vegas Neurology Center Las Vegas Nevada Recruiting
Dent Neurologic Institute - Amherst Amherst New York Recruiting
University of North Carolina at Chapel Hill-170 Manning Dr. Chapel Hill North Carolina Recruiting
Duke Early Phase Clinical Research Unit - PPDS Durham North Carolina Recruiting
University of Cincinnati Medical Center - Goodman St Cincinnati Ohio Recruiting
Ohio State Martha Morehouse Outpatient Care Columbus Ohio Recruiting
Erlanger Health System Chattanooga Tennessee Recruiting
National Neuromuscular Research Institute Austin Texas Recruiting
University of Texas- San Antonio - Health Science Center - PPDS San Antonio Texas Recruiting
UZ Leuven - PPDS Leuven Belgium Recruiting
Charité - Universitätsmedizin Berlin Berlin Germany Recruiting
Universitätsmedizin Göttingen Göttingen Germany Recruiting
Universitätsklinikum Würzburg Würzburg Germany Recruiting
Eginitio Hospital Athens Greece Recruiting
AHEPA University General Hospital of Thessaloniki Thessaloniki Greece Recruiting
ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII Bergamo Lombardy Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Lombardy Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy Recruiting
AORN Antonio Cardarelli Naples Italy Recruiting
University of Tsukuba Hospital Tsukuba Ibaraki Recruiting
St. Marianna University Hospital Kawasaki-Shi Kanagawa Recruiting
National Hospital Organization Sendai Medical Center Sendai Miyagi Recruiting
General Hanamaki Hospital - Kajomachi Hanamaki Japan Recruiting
IUHW Narita Hospital Narita Japan Recruiting
MICS Centrum Medyczne Bydgoszcz Bydgoszcz Kuyavian-Pomeranian Voivodeship Recruiting
Krakowska Akademia Neurologii Sp. z o.o. Krakow Lesser Poland Voivodeship Recruiting
Centrum Medyczne Neurologia Slaska Katowice Silesian Voivodeship Recruiting
Warszawski Uniwersytet Medyczny Warsaw Poland Recruiting
Hospital Regional Universitario de Malaga - Hospital General Málaga Malaga Recruiting
Hospital de La Santa Creu i Sant Pau Barcelona Spain Recruiting

More argenx trials in Belgium

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa Recruiting
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy Active, not recruiting
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis Active, not recruiting

Other trials for the same condition

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) Active, not recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07294170 on ClinicalTrials.gov ↗ ← All trials in Belgium